Treatment of cognitive impairment in multiple sclerosis: position paper

摘要: Cognitive impairment in multiple sclerosis (MS) is common, debilitating and burdensome. Key evidence from trials was reviewed to enable recommendations be made guide clinical practice research. Behavioural pharmacological interventions on cognition reported published studies were reviewed. Most evaluating behavioural treatment for learning memory, deficits of attention executive function have demonstrated some improvement. Controlled relapsing remitting MS indicate interferon (IFN) β-1b IFN β-1a associated with modest cognitive The effects symptomatic therapies such as modafinil donepezil are inconsistent. yielding positive findings significant methodological difficulties limiting the confidence making any broad recommendations. There no reports glatiramer acetate, natalizumab fingolimod being effective improving controlled trials. disease modifying other forms clinically isolated syndrome not yielded results. Data linking therapy, or treatment, either reducing decline impaired limited prevention needs remain a key research focus, identifying new trial methodology.